JPS58148826A - Glycoprotein and remedy for tumor - Google Patents

Glycoprotein and remedy for tumor

Info

Publication number
JPS58148826A
JPS58148826A JP57028992A JP2899282A JPS58148826A JP S58148826 A JPS58148826 A JP S58148826A JP 57028992 A JP57028992 A JP 57028992A JP 2899282 A JP2899282 A JP 2899282A JP S58148826 A JPS58148826 A JP S58148826A
Authority
JP
Japan
Prior art keywords
reaction
cbx
cells
tumor
shows
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP57028992A
Other languages
Japanese (ja)
Inventor
Haruo Onishi
治夫 大西
Kazuo Yamaguchi
和夫 山口
Yasuo Suzuki
泰雄 鈴木
Suguru Mochida
持田 英
Nobuo Mochida
持田 信夫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mochida Pharmaceutical Co Ltd
Original Assignee
Mochida Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mochida Pharmaceutical Co Ltd filed Critical Mochida Pharmaceutical Co Ltd
Priority to JP57028992A priority Critical patent/JPS58148826A/en
Priority to US06/467,840 priority patent/US4481137A/en
Priority to ZA831109A priority patent/ZA831109B/en
Priority to DE19833306297 priority patent/DE3306297A1/en
Priority to GR70607A priority patent/GR78097B/el
Priority to KR1019830000755A priority patent/KR840003694A/en
Priority to NL8300727A priority patent/NL8300727A/en
Priority to PT76296A priority patent/PT76296B/en
Priority to PL83240784A priority patent/PL240784A1/en
Priority to FI830638A priority patent/FI830638L/en
Priority to BR8300933A priority patent/BR8300933A/en
Priority to BE210211A priority patent/BE896027A/en
Priority to AU11850/83A priority patent/AU543634B2/en
Priority to DK93383A priority patent/DK93383A/en
Priority to SE8301073A priority patent/SE8301073L/en
Priority to ES520105A priority patent/ES520105A0/en
Priority to GB08305330A priority patent/GB2117385B/en
Priority to LU84662A priority patent/LU84662A1/en
Priority to NO830669A priority patent/NO830669L/en
Priority to RO110170A priority patent/RO85901B/en
Priority to DD83248327A priority patent/DD209634A5/en
Priority to FR8303274A priority patent/FR2522267A1/en
Publication of JPS58148826A publication Critical patent/JPS58148826A/en
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

NEW MATERIAL:A glycoprotein having the following properties: Molecular weight: 12,000-17,000. Color reactions: Coloring of the protein by the Lowry reaction, coloring of the peptide bond and the amino acid by the ninhydrin reaction after the hydrolysis with hydrochloric acid and coloring of the saccharide by the phenolsulfurinc acid reaction. Properties and solubility: White powder. Soluble in water and aqueous solution of NaCl, etc. and slightly soluble in benzene, etc. Saccharide content: 27-33%. Isoelectric point: 4.2-7.3. Adsorbable in a 0.01M phosphroric acid buffer solution (7.2pH) by specific fractionation procedures. USE:A remedy for tumors. PROCESS:A glycoprotein (CBx) having a very powerful and selective cytotoxic action on the tumorous cells and differentiation inductive action on the recovery of the tumorous cells to the normal cells is obtained by subjecting an extract or cultivation supernatant liquid of a reticuloendothelial cell, lymphoblast, leukemic cell or fibroblastic cell of a warm-blooded animal to a salting out treatment, ion exchange chromatography, gel filtration, affinity chromatography or dialysis, etc. A remedy for tumor is obtd. using said CBx as a main constituent.

Description

【発明の詳細な説明】 本発明はail血動物の網内系細胞、リンパ芽球。[Detailed description of the invention] The present invention relates to reticuloendothelial cells and lymphoblasts of ailing animals.

白血病HJ胞もしくは一紬芽II4鉋の抽出液または培
養上清からkll侍した新規なsl蛋白質およびこり糖
蛋白質を主成分として含有する腫瘍治ll1iIiiI
[114ijる。
Tumor therapy containing as main components a novel sl protein and glycoprotein extracted from the extract or culture supernatant of leukemia HJ cells or Ichitsumugi II 4 spores
[114ijuru.

実在、腫瘍の見金な薬物ft3#法はなく、これまで世
界各国の多数の研究者により多くの一瘍治瞭削が開発さ
れて来たに%かかわらず、依然として臨床においては新
しい治療薬や条鋼併用療法が試みられている。111%
の治療剤は、癌免疫療法剤と癌免疫療法剤に大別されて
いる。癌化学#法削は、いわゆる細l1M毒であり、a
胞の増殖を非籍異的に抑制することくよ)作用を発現す
るので、腫瘍細胞ばか夛でなく正常1m脂にも作用して
、白血球数少症、不妊、脱毛、催奇形、発癌など億めて
1篤1km作用を示すため、その使用IKは厳密なtm
限が設けられている。
In reality, there is no effective drug FT3 for treating tumors, and although many tumor-curing treatments have been developed by many researchers around the world, there are still new therapeutic agents and treatments in clinical practice. Combination therapy with long steel has been attempted. 111%
Therapeutic agents are broadly classified into cancer immunotherapeutic agents and cancer immunotherapeutic agents. Cancer chemistry #method is a so-called thin l1M poison, a
Because it exerts the effect of inhibiting cell proliferation in a non-discriminatory manner, it acts not only on tumor cells but also on normal fat cells, resulting in leukocyte count deficiency, infertility, hair loss, teratogenicity, and carcinogenesis. Since it exhibits a 1km action per application, the IK used must be strictly TM.
There are limits.

ヱた、癌免疫療法剤は5直接に膿瘍#鞄の増殖を抑制す
るのではなく、生体防#機能に鋤さかけてi5接的K1
1l瘍の壇PIiを抑制することにより治療作用を発現
するので癌化学&法剤に比して′N篤な制作用の発現は
他めで少ないが、腫瘍患@においては生体防#憬能か光
分残っていない場合も多く、その治MI効来は癌化学僚
法剤に比して必ずしも光分ではない。
In addition, cancer immunotherapeutic agents do not directly suppress the growth of abscesses, but directly inhibit K1 by acting on the biological defense function.
It exerts its therapeutic action by suppressing PIi in cancer, so compared to cancer chemical and legal drugs, its expression in severe production is less, but it has a biological defense function in tumor patients. In many cases, there is no light remaining, and the therapeutic effect of MI is not necessarily as light as that of cancer chemotherapeutics.

本発明者は、生体防両磯乾の中で皇要な役割を来してい
る網内系#I胞が!優を治療しうる物置を産生している
oJ能性かあると考え、多年にわたり@究をIftけて
米た。既に、網内系細胞からはリンホトキシンや腫瘍壊
死因子などと称する腫瘍治療効果の期待できる細胞障害
因子が採暖さn、それぞれ、グランジャーら((jra
ngeret al、、 Ce1lular 1mmu
nology、 58 %、  388〜402自、1
978年)およびカースウェルら(CarswellE
、 A、et at、、 t’roc、 Natl。A
cad、 Sci、 LJ、 S、A−、72巻、9号
、5666〜5670負、1975年)VCより報告さ
れている。11こ、最近、本発明者は、免疫能を弱めた
ハムスターに増殖させたりンパ芽球の培養漱申から、#
iEしたリンホトキシ/および腫瘍壊死因子などを併せ
含有する混合組成物としテ腫瘍破壊因子(Carcin
o−BreakingFactor、 IJ下CHFと
略称する。)を多l[、かつ、容易に分権することがで
き、このCBPかvJglJK移橿した実験腫瘍に有効
でるると発表(続発fr110.1981年、11月2
2日、朝刊ンして米た。本発明者は、仁のCBFの研究
過@において、さらに、龜nntIIJ物の網内系細胞
、リンパ芽球、白血病帷胞奄しくはi1維芽細聴の抽出
液または培養上溝に、#記したa胞障害因子などの1實
とは異なる糖蛋白質を見出し、この棚蛋白質か極めて強
力かつ選択的な一瘍細胞隊書作用ならびに腫瘍細胞を正
常に復する、いわゆる分化目毒作用などにより%僚づけ
られる腫瘍治療作用を封することを丸出し、本発明を完
成した。
The present inventor discovered that the reticuloendothelial system #I cells play an important role in the biological defense system of Ryoiso Inui! Believing that there was an oJ potential that could be used to treat Yuu, he spent many years researching it. Already, reticuloendothelial cells contain cytotoxic factors such as lymphotoxin and tumor necrosis factor, which can be expected to have a therapeutic effect on tumors. Granger et al.
ngeret al,, Ce1lular 1mmu
nology, 58%, 388-402 self, 1
978) and Carswell et al.
, A, et at,, t'roc, Natl. A
cad, Sci, LJ, S, A-, vol. 72, no. 9, 5666-5670 negative, 1975) reported by VC. 11.Recently, the present inventor has developed #
A mixed composition containing iE-treated lymphotoxy/and tumor necrosis factor, etc.
o-BreakingFactor, abbreviated as IJ CHF. ) can be easily decentralized, and it was announced that this CBP was effective against vJglJK-translocated experimental tumors (sequel fr110. 1981, November 2).
On the 2nd, I read the morning paper and went to bed. In the course of research on CBF by Jin, the present inventor further noted # in extracts or cultured cells of reticuloendothelial cells, lymphoblasts, leukemia cells, or i1 fibroblast cells of NntIIJ. We have discovered a glycoprotein that is different from the actual one, such as the A cell damage factor, and this shelf protein has an extremely strong and selective action on tumor cells, as well as a so-called differentiated eye poisoning action that restores tumor cells to normal. The present invention was completed by fully realizing the purpose of blocking the tumor therapeutic effect that is associated with cancer.

本発明のsr蛋白質(り下、本書質を■瘍破壊(I!’
lix 、すなわち、 Carcino−Breake
r Xと称し、CBXと略林する。)の物理的、化学的
ならびに生物学的諸性質を絆述する。
The sr protein of the present invention (I!')
lix, i.e. Carcino-Breake
It is called rX and abbreviated as CBX. ) to describe the physical, chemical, and biological properties of

+)  分子1t;士ファデックスG−1oo(ファル
マンア社)を用い、α01 M 17ン酸緩衝液(pH
7,2)をm課としてゲルP2Mを行ない分子tftI
llI定したところ、その分子量は、+2.ooo〜1
7,000でるる。
+) Molecule 1t; α01M 17 phosphate buffer (pH
7, 2) was used as section m to perform gel P2M, and the molecule tftI
llI was determined, and its molecular weight was +2. ooo~1
7,000 Ruru.

2)呈色反応:CBXの水#j液について呈色反応を試
験しγこ結果を第1衣に示す。なお、口IJ−および二
/ヒドリン反応は、生化学実験講座、■清、蛋白質定1
法、1971年記載の方法、フェノール硫tlI法、ア
ンスロン硫酸、ナフトール硫酸、インドール4A酸およ
びトリプトファン硫酸反応は、生化学実験1111L4
巻、a質足倉法、1971年記載の方法、 ホルン反応
は、生化学実験講座、3巻、脂質定を法、1971年記
載の方法に従って行なった。
2) Color reaction: The color reaction of CBX water solution #j was tested and the results are shown in Figure 1. In addition, the IJ- and di/hydrin reactions are described in Biochemistry Experiment Course, Sei, Protein Determination 1.
The phenol sulfur tlI method, anthrone sulfuric acid, naphthol sulfuric acid, indole 4A acid and tryptophan sulfuric acid reactions are described in Biochemistry Experiment 1111L4.
The Horn reaction was carried out according to the method described in Biochemistry Experiment Course, Vol. 3, Lipid Determination Method, 1971.

講 1 表 以上のように、CBxはタンノくり質および糖質の呈色
を示し、脂質の呈色は示さない。
Lecture 1 As shown in the table above, CBx exhibits the coloration of tannin and carbohydrates, but not the coloration of lipids.

5)性状・溶解性:白色粉末であり、水、塩化ナトリウ
ム水溶液およびリン#に緩*J液に可嬉でおり、がyイ
ン、ヘキナンおよびりO。
5) Properties/Solubility: It is a white powder and is easily mixed with water, aqueous sodium chloride solution, and phosphorus*J solution, and is easily mixed with yin, hequinane, and phosphorus.

ホルムに緻と、んと溶けない。It does not dissolve very well in foam.

4)  @含有量;CBxf)@含有菫およびその組成
をスビo (5piro、 H,A、、 Method
s 1o Easy −mology、 B舎、3〜2
6貞、1966年)の方法に準じて測定したM果、本I
III+債の細を有量は27〜65%でおり、さらにそ
の糖成分はヘキソース17〜20%、ヘキソサミン5〜
7%、7アル酸5〜6%である。
4) @Content; CBxf) @Contained violet and its composition Subio (5piro, H, A,, Method
s 1o Easy-mology, B Building, 3-2
M fruit measured according to the method of 6 Sada, 1966), book I
The content of III+ bonds is 27-65%, and its sugar components are 17-20% hexose and 5-5% hexosamine.
7%, 7alic acids 5-6%.

5)等電点、アンホラインを用いた等電点電気泳動にお
いて、CBxの等電点を測定したところ、4−2〜73
である。
5) Isoelectric point, when the isoelectric point of CBx was measured in isoelectric focusing electrophoresis using ampholine, it was 4-2 to 73.
It is.

6)ウレノクス ヨーロベウス アグルテニン結合セフ
ァデックスを用いた分VkJ操作において、001Mリ
ンM緩衝液(pH7,2)甲で吸着性である。
6) Urenox Europeus Adsorbent in 001M phosphorus M buffer (pH 7,2) A in a minute VkJ operation using agglutenin-bound Sephadex.

7)  pH1O1pH7,0もしくはpH1tOの水
溶液中、4℃において24時間以上、また、pH10の
水溶液中、60℃において3時間以上、CBxのゲルe
遇法による分子量および腫瘍細胞障害活性が安定である
7) CBx gel e in an aqueous solution of pH 1O1 pH 7.0 or pH 1tO at 4°C for 24 hours or more, and in an aqueous solution of pH 10 at 60°C for 3 hours or more.
The molecular weight and tumor cytotoxic activity are stable depending on the treatment method.

8)  +E常細鞄には実質市に障害を与えず、纏瘍細
@に選択的に障害倉与える。CBXの細胞障害性は、1
1]’−のIIa側rC本便質絵加下に。
8) The +E ever-thin bag does not actually cause any hindrance to the city, but selectively gives a hindrance to the ``skinny bag''. The cytotoxicity of CBX is 1
1]'- IIa side rC main fecal quality pictured below.

37℃、5%炭酸ガス含有酸素ガス通気下にて48時間
培養し、トリバンプルーによって染色されない生残細胞
数を計数し、50%増殖抑制績度で示した。不物質の1
率位は10″個のKB細胞の増殖を50囁抑制する一度
である。
The cells were cultured at 37° C. for 48 hours under aeration of oxygen gas containing 5% carbon dioxide, and the number of surviving cells that were not stained with trivan blue was counted and expressed as a 50% growth inhibition rate. immaterial 1
The rate is once the proliferation of 10'' KB cells is suppressed by 50 seconds.

?)骨髄性白血病a胞M−tを用いて、穂積らの方法(
Hozurni et aJ、、 Cancer Re
5earch40巻、2919〜2924貞、1980
年)に準じた試験において、腫瘍細胞の分化誘導作用す
なわち、腫瘍細胞を正常に復する作用を有゛する。
? ) The method of Hozumi et al. (
Hozurni et aJ, Cancer Re
5earch vol. 40, 2919-2924 Sada, 1980
In a test according to 2010, it has an effect of inducing differentiation of tumor cells, that is, an effect of restoring tumor cells to normal state.

CBXは網内系細胞、リンパ芽球、白血病細胞もしくは
縁維芽細胞から取得されるリンホトキシ/やmtiy壊
死因子などあるいはこれらの混合物であるCBFとは次
の点で明確に8別することができ、明らかに異なる物質
である。リンホトキシンは、その分子量から、7[IL
OOO〜9[LOOO,3a000〜5111)00゜
I Qo 00〜2 ilo LI Q(1)5 m、
すnゎb、α、βおよびr−リンホトキシンが存在する
ことか知られている( Cohenら−「8joJog
y of theLympk+okines J 、 
Academic )’ress 、 1979年)。
CBX can be clearly distinguished from CBF, which is composed of lymphotoxy/mtiy necrosis factor, etc. obtained from reticuloendothelial cells, lymphoblasts, leukemia cells, or limbal fibroblasts, or a mixture thereof, in the following points. , are clearly different substances. Lymphotoxin has a molecular weight of 7 [IL
OOO~9 [LOOO, 3a000~5111) 00°I Qo 00~2 ilo LI Q(1) 5 m,
It is known that snub, α, β and r-lymphotoxins exist (Cohen et al.
y of theLympk+okines J,
Academic)'ress, 1979).

この内、αおよびβ−リンホトキシンはその分子量から
明らかK CB xと異なる。さらrこ、r−’Jンホ
ト+シンは分子@ 1cLOOO〜2[LOOOの$1
誕白とグランジャーらにより細管さ扛ている( Gra
nger et al、、 Ce1lular II]
M]+unology。
Among these, α and β-lymphotoxins are clearly different from KCB x based on their molecular weights. Sararko, r-'Jnhot + Shin is a molecule @ 1cLOOO~2 [LOOO's $1
Gra
Ger et al., Ce1lular II]
M]+unology.

58 %、388〜402貞、1978年)が、 C:
Bxとは異な956℃、pH7,0の/X浴故申、50
分で不女建なw′Nでめ9、グランジャーらの方法に使
って−製し1こか子讃1G、0LIO〜2痣000ノI
Jンホトキシンはウレックス ヨーロベウス アグルテ
ニン結合セファデックスに対して、αQ1Mリン酸鹸伽
練甲で非吸着でめり、膿瘍−鞄にも正f#1iIj@に
も陣否を与え細胞障害Ffにおいて選択性は紹めりnな
い。
58%, 388-402 Sada, 1978), but C:
50
9, using Granger et al.'s method, I made 1 Kokakosan 1G, 0LIO~2 birthmarks 000noI.
J-nhotoxin is non-adsorbed to Ulex European agglutenin-bound Sephadex with αQ1M phosphoric acid, and is selective in cell damage Ff. There is no introduction.

閤瘍壊死因子は選択的に腫瘍dI@[対して障害作用を
示すことは前記のとおりだが、その分子量は54ouo
〜6へ000、糖含有量は0%(Carswell、 
E、^、et al、、 Proc、 INatl、A
cad。
As mentioned above, tumor necrosis factor selectively exhibits a damaging effect on tumor dI@, but its molecular weight is 54 ouo.
to 6,000, sugar content is 0% (Carswell,
E,^,et al,,Proc,INatl,A
cad.

Sci、 USA、  72%、9号、5666〜5b
70貞。
Sci, USA, 72%, No. 9, 5666-5b
70 sada.

1975 年) 1 fsk1分子1!Igooo、糖
含N1−が4Ω%(日本!!隣新聞: 1981年、8
月25日、朝刊)であり、前者の勧含1o%のものは、
柵蛋白質でない点で、後者の糖含有量40%のものは、
糖含有量の点で、また、両者とも分子量において、いず
れも、CBxとは異なっている。
(1975) 1 fsk1 molecule 1! Igooo, sugar-containing N1- is 4Ω% (Japan!! Neighbor Newspaper: 1981, 8
25th of the month, morning edition), and the former 10% recommendation is
In that it is not a fence protein, the latter one with a sugar content of 40% is
Both differ from CBx in their sugar content and in their molecular weight.

さらに、これらの−胞除害因子′fra−IrするCf
3Fは、インターフェロンよシ分子量の大きな資質(靜
両′#開、1981年11月21日、朝刊ンで分子量が
約3飄00Ω(日本経済新開、1981年月月228.
朝刊)でめり、明らかKCBxと異なっている。
Furthermore, these -cell removal factors'fra-Ir and Cf
3F has a molecular weight of about 300Ω (Nihon Keizai Shinkai, 1981, 228.
morning edition), which is clearly different from KCBx.

CBxは、一般に次のようにして権得することかで8る
〇 混血勧智の網内系細胞、リンパ芽球、白血病細胞もしく
は縁維芽aJI!Iの抽出液またはJ@養上溝を塩析、
イオン交換クロマトグラフィー、ゲル1遍、アフィニテ
ィークロマトグラフィー、透析など公知の方法を用いる
ことにより製造できる。この他、ヌードマウス、x4I
照射動物を用いて細@を大雪に増殖させることにより、
大1kK侍ることもできる。
CBx is generally acquired as follows: 8. Mixed race reticuloendothelial cells, lymphoblasts, leukemia cells or marginal fibroblasts aJI! Salting out the extract of I or J@Nyojo,
It can be produced by using known methods such as ion exchange chromatography, gel chromatography, affinity chromatography, and dialysis. In addition, nude mouse, x4I
By using irradiated animals to propagate Hoso@ into Daisetsu,
You can also hold a large 1kK samurai.

このようにして鯛造さtしたCHxについで5庫上に有
効性、毒性、用法および用普を述べる。
Next to the CHx produced in this way, we will discuss its effectiveness, toxicity, usage, and use.

実験tl  m胞障害作用のS択性 謔瘍im胞でめるKB(鼻咽腔罎)細胞、式−1(Wm
)−胞(鳩研究会、塚越茂博士より分与)、)−IEp
−2(咽−癌) 、 I−(El、 (肝癌)細胞(フ
ロラ社)、tFKdlnでおる一J−腸(Intes日
ne)407細胞、ジラルデ4 rL1緘(Girar
d+ 1(eart ) a@。
Experimental Tl KB (nasopharyngeal pharyngeal) cells, expression-1 (Wm
)-Bulle (Given by Pigeon Research Society, Dr. Shigeru Tsukagoshi), )-IEp
-2 (pharyngeal cancer), I-(El, liver cancer) cells (Flora), tFKdln-treated IJ-intestinal (Intes day ne) 407 cells, Girardet 4 rL1 scarlet (Girar).
d+ 1(eart) a@.

ナヤング肝(Chaog L+ver)4iid砲、べ
o (Vero。
Chaog L+ver 4iid gun, Vero.

サル箒ン細胞、MDCK (イヌ奸) tl&! (フ
ロラ社)k、そnぞれ、10″イ固あらかじめ24時1
司培養恢、P2S5およびL12+o (白血病)細胞
(癌研究会、塚越茂博士より分与)105鰺を直ちをで
、被検物質を龜加した10囁仔牛血清宮有イー グルf
@Jt!!xwt中で、37℃、5優炭酸ガス?Sむ酸
素ガス通気)に48時間培養しfこ。培*i了恢、トリ
パンフルーで染色さねない生残#I胞数を元手−像鏡下
に訂叙し、対照i 100として被検物質の50囁祷胞
丸滅譲震を「算した。
Monkey broom cell, MDCK (dog broom) tl&! (Flora Inc.) K, each, 10"
Tsukasa culture, P2S5 and L12+o (leukemia) cells (donated by Cancer Research Society, Dr. Shigeru Tsukagoshi) 105 mackerel were immediately taken, and the test substance was added to 10 whispers of calf serum.
@Jt! ! xwt, 37℃, 5 major carbon dioxide gas? Culture for 48 hours under oxygen gas aeration). After completing the cultivation, the number of surviving #I cells that do not stain with trypan flu was recorded under the microscope, and 50 small cells of the test substance were completely destroyed as control i100. did.

被検物質としては、後述する実施ガ2(シ造例)で得た
CBx、公知方法(Granger、 G、 A、 e
t al。
The test substances include CBx obtained in Example 2 (fabrication example), which will be described later, and CBx obtained by a known method (Granger, G, A, e
tal.

、 Ce1lular Irmuu+ology、 3
8 巻+ 588〜402 自、1978年)により@
侍し1こγ−リンホトキシン、後述する実施愕2(鯛造
偽)でCBxと分離さnたCHFならひにマイトマイシ
ンcl用いた。また、リンホトキシンおよびCBFの1
年位は、マウスL細胞に対する障害性を指標とする公知
の方法(Bloam、 B、R,&Qrade、 P、
 )t、共−[Invitro methods +n
 cell −mediated 1ttrnunit
y J^cademic Press、 197 ?年
ンにより表示した。結果を第2表に示した。
, Ce1lular Irmuu+ology, 3
Volume 8 + 588-402, 1978) @
In the case of Samurai 1, γ-lymphotoxin, and CHF, which were separated from CBx in Experiment 2 (Taizo sham) described later, mitomycin Cl was used. Also, lymphotoxin and CBF 1
The year is determined by a known method using the toxicity to mouse L cells as an index (Bloam, B, R, & Qrade, P,
)t, co-[Invitro methods +n
cell-mediated 1ttrnunit
y J^cademic Press, 197? Displayed by year. The results are shown in Table 2.

第 2 表 以上の結果から明らかなとおり、CBxはC8)゛と同
僚に正常Ia鞄に実質的には障害を与えることなく、−
瘍一側九遺択的に障害を与えた。ただし、各々の腫瘍細
胞[対する障害作用gilfは、CBxとCBF’との
闇で異なって囚た。
As is clear from the results shown in Table 2, CBx was able to improve C8) and co-workers' normal Ia bags without substantially impeding -
The tumor caused selective disability on one side. However, the damaging effect on each tumor cell [GILF] was different between CBx and CBF'.

これKnし1.−リンホトキシンおよびマイトマン/C
は、いずれも、止帛細胞および腫瘍細胞に対し、選択性
のない障害作用を示した。
This is Kn1. - Lymphotoxin and miteman/C
Both showed non-selective damaging effects on stopped cells and tumor cells.

実MH2”)’ルコーマ180およびエーリッヒ癌移殖
マウスに及ぼす影響 ザルコーマN10dll(、ニー’Jクヒiaj@t、
体fi25〜30fのddY系雄マウスに1匹当り3 
X 10’1jll−a腔内移罹し、生存日a會麹察し
た。恢遅する実施例1 (農造例)で侍たCBxを、1
群5匹のマウスに纏瘍移偕翌日より死亡mFifJ!で
連日静脈注射した。結果を対照群の平均生存日数を10
0として第3表に示した。
Real MH2'')'Effects of Sarcoma 180 and Ehrlich cancer transplanted mice on Sarcoma N10dll
3 per mouse for ddY male mice with a body fi of 25 to 30 f.
X 10'1jll-a intracavity metastasis occurred, and the patient was observed on the day of survival. The CBx that was served in Example 1 (agricultural example) was 1
Five mice in the group died the next day after developing a tumor mFifJ! I was injected intravenously every day. The average survival time of the control group was 10 days.
It is shown in Table 3 as 0.

第5表 以上の結果より、CB xはザルコーマ180およびエ
ーリソヒ癌のいずnを4IJ橿したマウスにおhても、
明らかな抗謔瘍作用を示した。
From the results in Table 5 and above, CB
It showed a clear anti-inflammatory effect.

実験愕5 白血病マウスの生存日eに及ぼす影響 体120〜25gの81)F、系雄マウスのD腔内に1
匹当4Q?0’@Q?’7ス白血病 L +21゜又は
106IllI!lのマウス白血病 P2S5を4!J
植し、生存日数を一察した。1畦を5匹として後述する
*)[2(製造例)で侍1コCB xを、移植翌日より
死亡直@まで連日腹腔内投与しfこ。結果を対照群の平
均生存日数を100として第4衣にボした。
Experimental Shock 5 Effects on survival day e of leukemic mice
4Q per game? 0'@Q? '7th leukemia L +21° or 106IllI! l mouse leukemia P2S5 4! J
I transplanted the seeds and estimated the number of days they survived. (Described later with 5 animals per row) [In 2 (manufacturing example), 1 Samurai CB x was intraperitoneally administered every day from the day after transplantation until immediately after death. The results were reported in the fourth column, with the average survival days of the control group being 100.

以上の結果よジ、CBxは、マウス白層病1.1210
およびマウス白血病 P388のいずれのm癌マウスに
おいても、明らかな抗−瘍作用を示した。
As a result of the above, CBx is mouse white layer disease 1.1210.
It showed a clear anti-tumor effect in both m-cancer mice and murine leukemia P388.

爽験偽4 肺癌マウスの生存日数に及ぼす影響体120
〜25#のB D F、糸雄マウスの石火MAs筋内内
[2X104@のルイス肺癌1m鞄を移債し、生存日数
を綾察した。1群を6匹として、後述する実Jlii例
3(負造例ンで侍たCBxを移植翌日より死亡直前まで
連日静脈注射した。結果を、対M群の平均生存日数を1
00として、第5表に示した。
Soken-sho 4 Influencing substances on survival days of lung cancer mice 120
~25 # of BDF, Itooma mice were intramuscularly transferred with 2 x 104 Lewis lung cancer 1 m bags, and the survival days were determined. One group was made up of 6 animals, and CBx, which was prepared using a negative injection tube (described later), was injected intravenously every day from the day after transplantation until just before death.
00 and shown in Table 5.

第5表 以上の結果より、CHxは、ルイスMJaMAsマウス
において、明らかに抗繍瘍炸用を示した。
From the results in Table 5 and above, CHx clearly showed an anti-inflammatory effect in Lewis MJaMAs mice.

実験例5 黒色腫マウスの生存日数に&はす影響 体120〜251のt3 D F、系雄マウスの背部皮
下10′個のマウス黒色#!816′ks檜し、生存日
数を観察した。1群7匹として、後述する実施肖2 (
II造愕)で傳たCBx を接種翌日より死亡II前ま
で連日静脈江射した。結果を対#@群の平均生存日数r
100として、第6表に示した。
Experimental Example 5 Effect on survival days of melanoma mice & lotus t3 DF of body 120-251, subcutaneous 10' mouse black # on the back of male mice! They were harvested for 816'ks and the number of days they survived was observed. A group of 7 animals was used in the experiment 2 (described later).
CBx, which had been given at the time of immunization (II), was injected intravenously every day from the day after inoculation until before death II. The results are expressed as the average survival days r for the #@ group.
It is shown in Table 6 as 100.

第6表 以上の結果よシCBxは、マウス黒色腫B16担噛マウ
スにおいて、明らかに抗纏瘍作用全示した。
According to the results shown in Table 6, CBx clearly exhibited anti-cancer activity in mice bearing melanoma B16.

実験?lj6  #Ihの肺転移におよrよ゛す影響1
群6匹の俸IL20〜501のB LI F、扇マウス
の背部皮下に、ルイス肺癌2■角片をS槙し、9日後よ
り12日間、後述する実1a例1 (負造例)で得たC
BxおよびCBFを1日1−静脈注射し、移1121日
後に原発巣腫瘍重量および肺転移結節数をウェクスラ(
Wexler、 H、)の方法 (J、Natj、Ca
ncer  In5tjtute、  3441.64
1負、1964年)K従って算定した。績at第7表に
示す。
experiment? Effect of lj6 #Ih on lung metastasis 1
A 2-inch square piece of Lewis lung cancer was placed subcutaneously on the back of a group of 6 BLIF and fan mice with an IL of 20 to 501, and after 9 days, for 12 days, the samples obtained in Example 1a Example 1 (negative example) described below were placed. C
Bx and CBF were injected intravenously once a day, and 1121 days after transfer, the weight of the primary tumor and the number of lung metastatic nodules were measured by Wexra (
Wexler, H.) method (J. Natj, Ca.
ncer In5tjtute, 3441.64
1 negative, 1964) K was calculated accordingly. The results are shown in Table 7.

第7表 表中の結果は平均値±IIA準誤差で示した。Table 7 The results in the table are expressed as mean value±IIA standard error.

拳危険*5%以下で対照#に比し、推計学的に有意の差
あり。
Fist risk *There is a statistically significant difference compared to control # at 5% or less.

鯖敢険事1囁以下で対照群に比し、推計学的(有意の!
!あり。
Compared to the control group, the Sabagan risk was less than 1 whisper (significant!
! can be.

以辷の結果より、CBxは@発巣の肺癌および肺転柊全
俸めて良く抑制したが、CBFは肺転移にほとんど効果
がなかった。
The results above showed that CBx suppressed the primary lung cancer and all metastases very well, but CBF had little effect on lung metastasis.

実験例7−瘍細胞の分化04作用 柵積らの方fiz (Hozumi、 M、et al
、、 CancerResearch、 404!、 
 2919〜2924日、  1980年)に従っfこ
。急性骨m性白血病細胞(M−1細胞、埼玉がんセンタ
ー、穂積本男博士より分与)SX+O″−を、あらかじ
め被検書質を添加しfこ常用の2倍量のアミノ酸ならび
にビタミンを含有する10ラウノ血清含有イーグル培地
11に浮遊させ、48時間、57℃、5囁炭酸ガス含有
#本ガス通気下[培養した。培養終了後。
Experimental Example 7 - Tumor Cell Differentiation 04 Effects (Hozumi, M, et al.
,, CancerResearch, 404! ,
2919-2924, 1980). Acute osteogenic leukemia cells (M-1 cells, provided by Dr. Motoo Hozumi, Saitama Cancer Center) SX + O''- were added with the test substance in advance, and twice the amount of amino acids and vitamins as usual. The cells were suspended in Eagle's medium 11 containing 10 Rauno's serum and cultured for 48 hours at 57° C. under a 5 minute gas aeration containing carbon dioxide. After completion of the culture.

02囁、メリステレンラテノクス粒子(ダウケミカル社
)含有1@地に^浮遊させ、57℃4時間珠1鏝、バー
チクルを貧食できるようになった細@叙と♀−胞叙倉、
尤学顧像鏡下に計数し、両画1@数の比から分化率を計
算し、結果を第8表に示す。
02 Whispers, containing 1 meristerene latenox particles (Dow Chemical Company), suspended in the ground, 57℃ for 4 hours, 1 trowel, and a small grain that became able to eat verticles.
The cells were counted under the microscope and the differentiation rate was calculated from the ratio of the numbers of both images, and the results are shown in Table 8.

第8表 CBxには分化#毒作用がみられ1こ。Table 8 CBx has a toxic effect on differentiation.

実験例8 発熱性試験 日本薬局方記載の試験法に従い、白色嫁先にfjt運す
る実施輿5で侍たCBxを、1匹当シ100率位静脈注
射し、3時間後fでの直腸自を熱電対式体I!i1計で
測定した結果を藁9表に示す。
Experimental Example 8 Pyrogenicity test According to the test method described in the Japanese Pharmacopoeia, CBx, which was delivered to a white bride in a 5-carrier, was injected intravenously at a rate of 100 per animal, and 3 hours later, the rectal Thermocouple body I! The results measured using the i1 meter are shown in Table 9.

第9表 CBxは発熱性を示さなかった。Table 9 CBx was not pyrogenic.

実験例8 毒性試験(1回投与) 捧120〜251のB L) F、  系層マウスを1
#10匹とし、後述する実験例2(股造肉)で侍たC 
Bx(i−静脈注射して7日間の死亡菌数を観察した1
、丈の結果、CBxICLQOO率位/時を投与しても
、坏貰、一般症状rc変化なく、10匹全肉か生存した
Experimental Example 8 Toxicity test (single administration)
#10 animals were used in Experimental Example 2 (meat production), which will be described later.
Bx (i-injected intravenously and observed the number of dead bacteria for 7 days 1
As a result, even after administering CBxICLQOO/hour, all 10 animals survived without any change in general symptoms.

夾験倒9 毒粁試験(60日間邊続投与)体ム20〜2
5JJのIJ D F、系層マウスを1群10匹とし、
後iEする実施レリ1 (製造向ンで侍だCBxを30
日間静静脈注射、死亡回数、14亜変+h、一般症状の
all祭を行なった。体重は午前9時から10時の闇に
測定し、一般症状の129は、アーダインの方法(5c
ience、 156巻。
9 Poison test (continuous administration for 60 days) Body weight 20-2
5JJ IJD F, 10 mice per group,
After iE implementation Reli 1 (Samurai CBx for manufacturing 30
Daily intravenous injections, number of deaths, 14 subtypes + hours, and all general symptoms were performed. Body weight was measured between 9:00 am and 10:00 am, and 129 of the general symptoms were measured using the Ardine method (5c
ience, vol. 156.

123自、1962 年)ニ準じ% in、20.30
日月例行なった。M果とシテ、CkJx  を、  1
.ODD単位/IF/日投与によって50日間に死亡的
はなく、体ムIIII加囲栂も対照群と差かみられなか
った。まfこ、一般症状においても対照群と同機に、異
常t−認めなかった。
123, 1962) % in, 20.30
I did it every day and every month. M fruit and shite, CkJx, 1
.. There were no fatalities during 50 days after administration of ODD units/IF/day, and no difference was observed in body mass III circulatory toga compared with the control group. Regarding general symptoms, no abnormalities were observed in the control group and the same aircraft.

以上の実験例から明ら°かなように、CHxは膿瘍m鞄
(選択的な増殖抑制作用を示し、癌爾1!@を正常11
41jiK分化させる作用を有し、しかも癌転移を著量
に抑制するばかりでなく、極めて多種多様の−flrK
有効てめったにもかかわらず、これらの薬理作用を示す
用tK比して光分高い用量においても、fつたく安全で
あp、腫瘍の治療に用いて極めて有用である。
As is clear from the above experimental examples, CHx exhibits a selective growth-inhibiting effect on abscess cells (cancer 1!@) and normal 11.
It not only has the effect of 41jiK differentiation and significantly suppresses cancer metastasis, but also has an extremely wide variety of -flrK
Although they have rarely been effective, they are extremely safe and extremely useful in the treatment of tumors, even at doses much higher than those of the tKs that exhibit these pharmacological effects.

CBxは1通常用いられる投与法である注射剤、点赦剤
、点鼻剤、歇λ剤、外用剤、経口投与用削、l1Jii
&投与用剤、腟内投与用剤などに用いることができる。
CBx is available in 1 commonly used administration methods such as injections, amends, nasal drops, temporal preparations, external preparations, oral preparations, and l1Jii.
It can be used for & administration preparations, intravaginal administration preparations, etc.

また、CBxの成人1日当りの治療量は、その安全性か
ら考えて、’fliK@定するまで4ないが、α5単位
〜50[LOOG率位であり、さらに好ましくは、局所
通用(おいてはα5〜aooo率位、静脈注射、筋肉注
射などの全#注射においては20〜too、cloO率
位、軽口投与においては、50〜50α000単位でら
り、用法るるいは症状に応じて適宜増減することかでさ
る。
In addition, considering its safety, the daily therapeutic dose of CBx for adults is not yet determined until it is determined, but it is α5 units to 50 [LOOG], and more preferably, it is locally applicable (in α5 to aooo, 20 to too for all injections such as intravenous injection, intramuscular injection, cloO, 50 to 50 α000 units for light administration, and increase or decrease as appropriate depending on usage and symptoms. It's a monkey.

CBxは任意慣用の製薬用担体、基剤あるいは賦IV3
削とともに慣用の方法で医薬用ll!!削とする0とが
できる。軽口投与剤としてはカプセル剤、錠削、数制な
どのlih浴製嗣、直腸内投与4jとしては直jlI坐
削、注射剤としては水溶性注射剤、あるいは用量におい
て注射用蒸留水に俗鱗して!用する凍結乾!I庄射削、
外用剤としては軟1t11i]Iあるいはローンシンと
して用いるのが好ヱしい。このほか、点眼鋒]、点鼻剤
もしくは吸入削として用いるCともできる。以下に、実
施めを示すか1本@明はこnに限定されるものではない
CBx may be any conventional pharmaceutical carrier, base or excipient IV3.
Medical use with cutting and customary methods! ! You can erase and zero. For light administration, there are capsules, tablets, tablets, etc., for intrarectal administration, there are 4J for rectal administration, for example, for intrarectal administration, there are water-soluble injections, and for the dosage, there are various types such as distilled water for injection. do! Use freeze drying! Isho shooting,
As an external preparation, it is preferable to use it as a soft 1t11i]I or as a lawn thin. In addition, it can also be used as eye drops], nasal drops, or inhalation powder. The implementation is shown below, but the method is not limited to this.

真流的1 (製造例) ヒト末梢リンパ球2×10″l鎮f 4,000dの1
0囁仔牛血清含有イーグル培地に浮遊させ、フィトヘマ
グルテニ/(ディフコ仕)を50μg、/xlとなるよ
うt&山し、57℃、5%炭鈑ガスさ有酸素ガス通気下
、48時I′ii1培養する。培書終了彼、上清をCL
(NMリン*駿伽敲(pH7,2)に透析後、40〜8
0囁m安塩析1111分を匈る。この−分を、再び前記
のリン#IIItaI液に透析価、竜ファデックスG−
100(ファルマシア?f) を用イー’(ゲルFiM
t行6Ln、 分子112,000〜17,000の分
−を得、粗CBxj分とし、それ以前に溶出し7S:画
分を粗CBF−分とした。粗CBx&Or、’)レクク
ス ヨーロペウス アグルテニン(丸善石油)iM合セ
フ7デツクスに吸着させ、rLsMフコース含有αot
M+7ン離緩衝液で溶出後、透析によりフコ〜スt−除
いて^ぴウレックス ヨーロベウス アグルテニン結合
セファデックスに@、着させてリン酸緩術液(pH7,
2)osWtt−徐々Kj%める、いわゆるグラジェン
ト方式でCBxを浴出した。このようにして、CBxt
 Ogg#t−得る。このよう和して得られたCBxの
活性は、IQOOO単位であり、Ii白1mpfiりの
比活性は10,000率位/wa1であった。
True flow 1 (manufacturing example) human peripheral lymphocytes 2 x 10"l 1 of 4,000d
Phytohaemaggluteni/(manufactured by Difco) was suspended in Eagle's medium containing 0.0 whisper calf serum, and 50 μg/xl of phytohemagglutenic acid was added at 57° C. under 5% charcoal gas and aerobic gas aeration at 48:00 I. 'ii1 culture. After completing the culture, remove the supernatant.
(40-8 after dialysis against NM phosphorus
0 whisper m ammonium salt precipitation 1111 minutes. This amount was dialyzed again into the above-mentioned phosphorus #IIItaI solution.
100 (Pharmacia?f) for E' (Gel FiM)
A fraction of molecules 112,000 to 17,000 in row t 6Ln was obtained and designated as the crude CBxj fraction, and the 7S: fraction eluted before that was designated as the crude CBF fraction. Crude CBx&Or,') Rex European agglutenin (Maruzen Sekiyu) adsorbed on iM Gosef7dex, rLsM fucose-containing αot
After elution with M+7 separation buffer, the fuco-st-t- was removed by dialysis, applied to agglutenin-bound Sephadex, and phosphate buffer solution (pH 7,
2) osWtt-CBx was extracted using a so-called gradient method in which Kj% was gradually reduced. In this way, CBxt
Ogg#t-obtain. The CBx activity obtained by the above summation was in IQOOO units, and the specific activity of Ii white 1mpfi was 10,000 degrees/wa1.

実施fi12 (製造例) ヒ ト BALL −1d@  (Miyosbi、N
ature、117巻 、843〜844 頁、197
7年)9 X 10”@i1.800gjの10う仔牛
血清含有イーグルj@地に浮遊さゼ、センダイウィルス
f 9 X 10’ pfu添加し、67℃、5%炭酸
ガス含有#素ガス通気下、48Qf′!l培11&、上
?’1flij!JliiiM 1 ノア1rffi[
従ってFl製した。このようにしてCBx720μtt
−侍ることかできる。このようにして祷られたCBxの
活性はZ920単位であり、比活性は+ 1.000率
位/ nipでめっ1こ。
Implementation fi12 (Production example) Human BALL-1d@ (Miyosbi, N
ature, vol. 117, pp. 843-844, 197
7 years) 9 X 10"@i 1.800 gj of 10 calf serum containing Eagle j@ floating on the ground, Sendai virus f 9 X 10' pfu added, 67°C, 5% carbon dioxide gas containing , 48Qf'!l culture 11&, top?'1flij!JliiiM 1 Noah 1rffi[
Therefore, Fl was made. In this way, CBx720μtt
-Can serve as a samurai. The activity of CBx thus obtained is Z920 units, and the specific activity is +1.000%/nip.

実Jll肉6(製造内) ヒト線維JJ細胞70つ7000細胞(70つ社)5 
X 10” @ t−600dの10%仔牛血清含有イ
ーグルj@地に浮遊させ、フィトヘマグルチニンを終#
度50μy/xlKなるように添加して、57℃、5囁
縦酸ガス含1[木ガス通気下、48時115J@養後、
上清を実施例1の方法に従って梢製した。このようにし
てCBx 60μi5r侍ることができる。このように
して祷られたCHxの活性は480率位であり、比活性
はa000率位/’wgであった。
Real Jll meat 6 (in production) Human fiber JJ cells 70 7000 cells (70 companies) 5
X 10" @ t-600d was suspended in Eagle J @ ground containing 10% calf serum to finalize phytohemagglutinin.
50 μy/xlK at 57°C, 5 min.
The supernatant was purified according to the method of Example 1. In this way, CBx 60μi5r can be used. The activity of CHx thus determined was 480 degrees, and the specific activity was a000 degrees/'wg.

*m例4(水浴性注射剤) CBx         20へ000率位塩化ナトリ
ウム     9. Oj 注射用蒸留水にて全t  i、000j+1本物質およ
び塩化す) リウムを秤量して混合した後、注射用蒸留
水500 xi K溶解し、更に注射用蒸留水で全tt
t、ooodとする。この水浴液を、メンブランフィル
タ−を用いて無菌的にP通し、e液を滅−したガラス谷
4に2dずつ光填して蜜秒し、水溶性注射剤とした。
*Example 4 (water bath injection) CBx 20 to 000 sodium chloride 9. Oj Total t i, 000j + 1 substance and chloride in distilled water for injection) After weighing and mixing lium, dissolve in 500 xi K of distilled water for injection, and then add total tt with distilled water for injection.
Let t,oood. This water bath solution was aseptically passed through a membrane filter, and the e-liquid was sterilized through glass valleys 4, each of which was filled with light for 2 d, to give a water-soluble injection.

実施例5 (凍結乾燥注射剤) CB x        xoc4ooo率位20%ヒ
ト血清アルブミン 10II+7注射用蒸留水にて全量
  t、on口dCBxHよひ塩化す) I)ラムを押
目して混合した後、注射用蒸留水500xlK所定量の
ヒト崩清アルブミンt−加えた水浴液KI@解し、lf
![注射用蒸留水で全1ifr1,001]t/とする
。この水浴液を、メンブランフィルタ−を用いて無−的
Kf’通し、2xlずつ畝−したガラス谷鵡に光填し、
凍結乾燥する。これをV!5秒し、凍結乾燥粉末製剤と
した。
Example 5 (Freeze-dried injection) CB x xoc4ooo 20% human serum albumin 10 II + 7 total volume with distilled water for injection (t, on-mouth dCB x H chloride) I) Press the ram and mix, then prepare for injection Distilled water 500xlK predetermined amount of human disintegrated albumin t-added water bath solution KI@dissolved, lf
! [Total 1ifr1,001 with distilled water for injection]t/. This water bath liquid was passed through an inert Kf' membrane filter and filled with light into a glass valley with 2xl ridges.
Freeze dry. V this! After 5 seconds, it was made into a lyophilized powder preparation.

実施例6 (点眼剤) CHx        too、ooo率位1化ナトリ
ウム     5t グロロブタノール    5# 注射用#留水にて全111口001 f:配各成分を秤量して950酊の注射用蒸留水に溶解
−[る。全1を+、000dにしてメンブランフィルタ
−を用い、無菌的に1壊して点眼剤とした、 5A! 残肉 7 (坐剤jン CBx         IOQ、000率位ポリエチ
レングリコール1500 250  #ポリエチレング
リコール 4000約750  #1.000j+ 上記各成分を秤重し、CBxおよびポリエチレングリコ
ール1500の全音、およびポリエテレ/グリコール4
0000500I會まく信相し。
Example 6 (Eye drops) CHx too, ooo Sodium monoxide 5t Globutanol 5# For injection #Total 111 mouths in distilled water 001 f: Weigh each ingredient and add to 950 ml of distilled water for injection. Dissolution - [ru. All 1 was changed to +,000d, and 1 was broken aseptically using a membrane filter to make an eye drop, 5A! Residue 7 (Suppositories CBx IOQ, 000% polyethylene glycol 1500 250 #Polyethylene glycol 4000 approx. 750 #1.000j+ Weigh each of the above components, and calculate the whole tone of CBx and polyethylene glycol 1500, and polyethylene glycol 4
0000500I We will meet each other and trust each other.

さらl!M!:lのポリエチレングリコール4000i
加えて全倉!t1,0ΩOtとしてよく信相して浴融法
により5,000■の直腸坐削とした。
Saral! M! :l polyethylene glycol 4000i
In addition, all warehouses! t1, 0ΩOt, and a 5,000 square rectal excision was made using the bath melting method with good agreement.

実施例8(点鼻斉0 CHx        10(LOOO4ilQ塩化ナ
トリウム      5を タロロフタノール    5を 蒸留水にて全ii1,000ILt 上記各成分を秤量し、950dの水に溶解して放冷恢、
全i11,000mに希釈し、点鼻削とする。
Example 8 (Nasal Drop) 0 CHx 10 (LOOO4ilQ Sodium Chloride 5 to Talolophthanol 5 to Distilled Water Total ii 1,000 ILt) Each of the above components was weighed, dissolved in 950 d of water and left to cool.
Dilute to 11,000m total and use as nasal spray.

実施例9 (腸溶性錠剤) Ctlx        LOOFILO00$fQ乳
II          6毛Ot ポテト#粉    約3nop ポリビニールアルコール    407ステアリン酸マ
グネシウム   五0t1.000を 上記成分倉それぞれ秤量したのち、CBxおよび乳権の
各金倉、およびポテト澱粉の約半量を混合し、さらに洩
りのポテト#粉を加えて音量を94.0gとして均一に
混合する。この1合物にポリビニールアルコールの水浴
液を加え、湿式顆粒造粒法により顆粒を調整する。この
顆粒を乾燥し、ステアリン酸マグネシウムを混和した価
圧縮打綻して、1量20Qジlの錠剤を製造するこれに
メチルセルロース7タレートをコーティングして!II
k解性綻削とした。
Example 9 (Enteric coated tablet) Ctlx LOOFILO00$fQ Milk II 6 hairs Potato #flour Approximately 3 nops Polyvinyl alcohol 407 Magnesium stearate 50 tons 1.000 were weighed in each of the above component warehouses, and then each of the CBx and milk rights warehouses, Mix about half of the potato starch and potato starch, and add the remaining potato flour to a volume of 94.0 g and mix uniformly. A water bath solution of polyvinyl alcohol is added to this mixture, and granules are prepared by a wet granulation method. The granules are dried and compressed with magnesium stearate to produce tablets of 20Q liter each, which are then coated with methylcellulose 7 talate. II
It was assumed to be a k-resolved fracture.

実7HM10(軟膏剤) CBx        10G、000率位波動パラフ
ィン     101 ワセリ/     幻1.00Of 1.0001 上記成分をそれぞn抑Iした債、CBxを波動パラフィ
ンに信相し、500 pのワセリンを加えてよく混合す
る。これ[残りのワセリンを加えてゆき、全*k i、
000 tとし、よく混和して軟を嗣とした。
Fruit 7HM10 (ointment) CBx 10G, 000% wave paraffin 101 petrolatum / illusion 1.00Of 1.0001 The above ingredients are suppressed by n, CBx is mixed with wave paraffin, and 500 p of petrolatum is added. Mix well. Add the remaining petroleum jelly, add all*k i,
000 t, and mixed well to obtain a soft consistency.

(ほか1名) 手続補正書 L 事fl−ノ衣示1.(和57年 特許1[第289
91、発明の名杓、 J11M白質ふ・よびWl瘍#I療剤 :i hli正する考 り巨1.ヒの関係 特杵出顧入 名称i山M¥株式会社 4 、 1’ l    理  人 5、補11錨Y合の19fす 7、補正のVi8 txt  嘴隷書薦12真第6行き−」繭7行の間に[
また、繍fIk−纏因子は1分子量がゲル証通法によ勢
5亀OOOであ抄、pH3以下では不安定であり、Co
tAJ會セファロースに吸着しないとの報告(Mjcm
a*I、 K 、  B 、 & George、  
E 。
(1 other person) Procedural Amendment L Matters Fl-No. 1. (Japanese Patent 1 [No. 289
91. Master of invention, J11M white matter tumor and Wl tumor #I treatment: i hli corrective idea 1. Relationship between special pestle and investment name Iyama M ¥ Co., Ltd. 4, 1' l Rijin 5, Supplementary 11 Anchor Y combination 19fsu 7, amendment Vi8 txt 崴Reisho recommendation 12 True 6th line -' Mayu 7 Between the lines [
In addition, the molecular weight of the fIk-component factor is 5 mm OOO according to the gel certification method, and it is unstable at pH 3 or less, and Co
It has been reported that tAJ does not adsorb to Sepharose (Mjcm
a*I, K, B, & George,
E.

G 、 、 J 、  I suaauaeJogy 
*  125巻、14i71〜1aj77Ji、 19
80年)、あるいは分子量が、ゲルー過法によ知、3亀
000で、糖をほとんど3まないとの#告 (Matt
hews、 N 、  at al 、 Brjt。
G, , J, I suaauaeJogy
*Volume 125, 14i71-1aj77Ji, 19
1980), or the molecular weight is 3,000, determined by the gel filtration method, and contains almost no sugar (Matt
hews, N., at al., Brjt.

J 、 Caxzcer、 42舎、  411〜42
211 、1980年)などもあるが、これらの物理化
学的性質−CBzとは異なっている。」を挿入する。
J, Caxzcer, 42nd House, 411-42.
211, 1980), but their physicochemical properties are different from those of CBz. ” is inserted.

(2)  明細llF縞12廁繭II行と同第12行の
闇にFさらに、CBxd後述する爽−NK示すように、
そonmnm浄書作用び仇腫瘍作用に徳%J4性がな(
、CBxの細胞障害作用が諸瘍−胞に適IR市であるの
に対し2インメー7エロンは公却のとお伽その作用に檎
%真性があり、a麿障沓作用が麿瘍鯛胞に遇式的でない
OでCBxとインターフェロンは区NJt”廊!。
(2) Specification 11 F stripes 12 line II line and F in the darkness of the same line 12.Furthermore, as shown in the CBxd So-NK mentioned later,
Soonmnm there is a virtue% J4 characteristic in the writing action and the enemy tumor action (
, whereas the cytotoxic effect of CBx is suitable for various tumor cells, the 2-in-7 elongation has a true nature in its effect, and the cytotoxic effect of CBx is suitable for various tumor cells. CBx and interferon are not formal O.

また、CBx/d抗ウィルスつ川【有さ用い点で鴫イン
ターフェロンと#isなっていル、」を挿入する。
Also, insert the following text: CBx/d antiviral #is used as interferon.

Claims (2)

【特許請求の範囲】[Claims] (1)  次の性質を有するm蛋白質:■ 分子量;1
2,000〜17. L) 0 G、■ 呈色反応;ロ
ーリ−反応により蛋白質の呈色を示し、塩酸加水分解後
のニンヒドリン反応においてペプチド結合およびアミノ
酸の呈色を示し、フェノールii*反応、アンスロン硫
酸反応、インドールits反応、トリグト7アンii酸
反応によりli類の呈色を示す。 ■ 性状・溶解性;白色粉末であり、水、塩化す) 1
7ウム水嬉液およびリン酸緩衝液に1嬉であシ、ベンゼ
ン、ヘキナンおよびクロロホルムに#とんと溶けなi% ■ 巻金有量か27〜55%であり、その組成が、ヘキ
ソース17〜20%、ヘキソサミン5〜7%、シアル#
5〜6%である、 ■ 等電点;く2〜Z3、 ■ ウレックス ヨーロベウス アグルデニン(Ule
x europeus  agglutjnin )結
合セファデックスを用いた分−操作において、101M
リン酸緩衝液(pH72)  中で吸着性である、 ■ pH2,0,pHz04L<t!pHtto (D
水溶液中、4℃において24時間以上安定であり、また
、pHzoの水溶液中、60℃において5時間以上安定
である、 ■ 正常細胞には実質的に障害を与えず、義1IIIA
胞に選択的に障害を与える、■ 腫@m胞の分化#毒作
用を有する。
(1) m protein with the following properties: ■ Molecular weight; 1
2,000-17. L) 0 G, ■ Color reaction; Lowry reaction shows protein coloration, ninhydrin reaction after hydrochloric acid hydrolysis shows peptide bond and amino acid coloration, phenol ii* reaction, anthrone sulfuric acid reaction, indole its It shows the coloration of li class due to the reaction, Trigto-7-amino acid reaction. ■ Properties/Solubility: White powder, chlorinated in water) 1
It is 7% soluble in water and phosphate buffer, and very soluble in benzene, hequinane and chloroform.The amount of metal is 27-55%, and its composition is 17-20% hexose. %, Hexosamine 5-7%, Sial #
5-6%, ■ Isoelectric point;
x europeus agglutjnin) In a minute-operation with combined Sephadex
Adsorbent in phosphate buffer (pH 72), ■ pH 2,0, pH 04L<t! pHtto (D
Stable in an aqueous solution at 4°C for 24 hours or more, and stable in an aqueous pH solution at 60°C for 5 hours or more; ■ Substantially does not cause damage to normal cells;
selectively damages cells; ■ Tumor @ m cell differentiation; Possesses a toxic effect.
(2)  次の性負を有するm蛋白質を生成分として含
有する腫瘍治療剤: ■ 分子量;t2.ooo〜17.’000゜■ 呈色
反応;ローリ−反応によ)蛋白質の呈色を示し、塩酸加
水分ps*のニンヒドリン反応においてペプチド結合お
よびアミノ酸の呈色を示し、フェノ−ルミ1m反応、ア
ンスロン[1反応、インドール(]i1#R反応、トリ
プト777硫酸反応によりsW4の呈色を示す、 ■ 性状・48解性;白色粉末でおり、水、塙化す) 
IJウム水水散液よびリン酸緩衝液に可溶でオリ、ベン
ゼン、ヘキサンおよびクロロホルムKaとんど溶けない
、 ■ 糖含有量が27〜33%であり、その組成が、ヘキ
ソース17〜20%、ヘキソサミン5〜7%、シアル@
5〜6%である、 ■ 21!電点;4.2〜7.5、 ■ ウレンクス ヨーロペウス アグルチニン結合セフ
ァデククスを用いた分−操作において、αO1Mリン#
緩衝液(pH7,2)中で吸着性でるる、 ■ pH1O、pH7,0もしくはpH1toの水溶液
中、4℃に−おいて24時間以上安定であり、また、p
H7,0の水f#液液中60℃におイテ3時間以上安定
である、 ■ 正g!胞には実質的に障害を与えず、腟瘍績J@に
選択的[障害を与える、 ■ 腫瘍細胞の分化#4作用を有する。
(2) A tumor therapeutic agent containing m protein having the following characteristics as a product: ■ Molecular weight; t2. ooo~17. '000゜■ Color reaction; Shows the color of proteins (by Lowry reaction), shows the color of peptide bonds and amino acids in the ninhydrin reaction of hydrochloric acid hydrochloride ps*, shows the color of peptide bonds and amino acids in the phenolumi 1m reaction, , indole (]i1#R reaction, exhibits sW4 coloration by trypto-777 sulfuric acid reaction, ■Properties/48 degradability; white powder, solidified with water)
It is soluble in IJum aqueous dispersion and phosphate buffer, but hardly soluble in benzene, hexane and chloroform. ■ Sugar content is 27-33%, and its composition is 17-20% hexose. , Hexosamine 5-7%, Sial@
5-6%, ■ 21! Electrical point; 4.2-7.5, ■ Urencus europaeus αO1M phosphorus #
Adsorptive in buffer solution (pH 7.2); ■ Stable for more than 24 hours at 4°C in an aqueous solution of pH 1O, pH 7.0 or pH 1to;
Stable for more than 3 hours at 60℃ in H7.0 water f# liquid. ■ Positive g! It has a selective effect on tumor cell differentiation, without causing substantial damage to vaginal tumors.
JP57028992A 1982-01-26 1982-02-26 Glycoprotein and remedy for tumor Pending JPS58148826A (en)

Priority Applications (22)

Application Number Priority Date Filing Date Title
JP57028992A JPS58148826A (en) 1982-02-26 1982-02-26 Glycoprotein and remedy for tumor
US06/467,840 US4481137A (en) 1982-02-26 1983-02-18 Glycoproteins and processes for their production
ZA831109A ZA831109B (en) 1982-02-26 1983-02-18 Glycoproteins,processes for their production and therapeutic agents for tumors which contain such glycoproteins
DE19833306297 DE3306297A1 (en) 1982-02-26 1983-02-23 NEW GLYCOPROTEINS, METHOD FOR THEIR PRODUCTION AND THERAPEUTIC AGENTS CONTAINING SUCH GLYCOPROTEINS AGAINST TUMORS
GR70607A GR78097B (en) 1982-02-26 1983-02-24
KR1019830000755A KR840003694A (en) 1982-02-26 1983-02-24 Method for preparing tumor therapeutic agent containing novel glycoprotein
NL8300727A NL8300727A (en) 1982-02-26 1983-02-25 NEW GLYCOPROTEINS, METHODS FOR PREPARING THE SAME AND THERAPEUTIC ANTI-TUMOR AGENTS CONTAINING SUCH GLYCOPROTEINS.
PT76296A PT76296B (en) 1982-02-26 1983-02-25 Novel glycoproteins processes for their production and therapeutic agents for tumors which contain such glycoproteins
PL83240784A PL240784A1 (en) 1982-02-26 1983-02-25 Process for preparing novel glycoproteins
FI830638A FI830638L (en) 1982-02-26 1983-02-25 FREQUENCY FRAMING FOR GLYCOPROTEINING
BR8300933A BR8300933A (en) 1982-02-26 1983-02-25 SUBSTANTIALLY PURIFIED FORM OF A GLYCOPROTEIN (CB) AND PROCESS FOR ITS PRODUCTION
BE210211A BE896027A (en) 1982-02-26 1983-02-25 NOVEL GLYCOPROTEINS, PRODUCTION METHODS AND THERAPEUTIC AGENTS FOR THE TREATMENT OF TUMORS CONTAINING THE SAME
AU11850/83A AU543634B2 (en) 1982-01-26 1983-02-25 Production of novel glycoproteins and therapeutic compositions containing them
DK93383A DK93383A (en) 1982-02-26 1983-02-25 GLYCOPROTEINES AND PROCEDURES FOR PREPARING IT
SE8301073A SE8301073L (en) 1982-02-26 1983-02-25 NEW GYCLOPROTEINES, PROCEDURES FOR PREPARING IT AND THERAPEUTIC AGENTS CONTAINING THEM
ES520105A ES520105A0 (en) 1982-02-26 1983-02-25 A PROCEDURE FOR OBTAINING A GLYCOPROTEIN (CB) THAT HAS AN ANTI-TUMOR EFFECT.
GB08305330A GB2117385B (en) 1982-02-26 1983-02-25 Antitumor glycoprotein
LU84662A LU84662A1 (en) 1982-02-26 1983-02-25 NOVEL GLYCOPROTEINS, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC AGENTS CONTAINING SUCH GLYCOPROTEINS FOR THE FIGHT OF TUMORS
NO830669A NO830669L (en) 1982-02-26 1983-02-25 NEW Glycoproteins, procedures for their preparation, and therapeutic preparations for tumors containing such glycoproteins
RO110170A RO85901B (en) 1982-02-26 1983-02-26 Process for preparing a glycoprotein with antitumour effect
DD83248327A DD209634A5 (en) 1982-02-26 1983-02-28 PROCESS FOR THE PREPARATION OF NEW GLYCOPROTEINS AND THEIR USE IN THERAPEUTIC AGENTS AGAINST TUMORS
FR8303274A FR2522267A1 (en) 1982-02-26 1983-02-28 GLYCOPROTEINS WITH ANTITUMOR ACTIVITY, PROCESS FOR PREPARING THEM AND THEIR THERAPEUTIC APPLICATION

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP57028992A JPS58148826A (en) 1982-02-26 1982-02-26 Glycoprotein and remedy for tumor

Publications (1)

Publication Number Publication Date
JPS58148826A true JPS58148826A (en) 1983-09-05

Family

ID=12263905

Family Applications (1)

Application Number Title Priority Date Filing Date
JP57028992A Pending JPS58148826A (en) 1982-01-26 1982-02-26 Glycoprotein and remedy for tumor

Country Status (3)

Country Link
JP (1) JPS58148826A (en)
KR (1) KR840003694A (en)
ZA (1) ZA831109B (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1984002912A1 (en) * 1983-01-31 1984-08-02 Otsuka Pharma Co Ltd Protein with oncostatic effect, process for its preparation, and oncostatic drug containing it
JPS6048931A (en) * 1983-08-29 1985-03-16 Yoshio Sakagami Tumor cell proliferation inhibiting factor consisting of novel protein
JPS6230725A (en) * 1985-04-10 1987-02-09 Denichi Mizuno Novel protein, production thereof and antitumor agent containing same
WO1990010651A1 (en) * 1989-03-10 1990-09-20 Snow Brand Milk Products Co., Ltd. Glycoprotein of human origin, physiologically active factor comprising the same, and pharmaceutical preparation containing the same as active ingredient

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1984002912A1 (en) * 1983-01-31 1984-08-02 Otsuka Pharma Co Ltd Protein with oncostatic effect, process for its preparation, and oncostatic drug containing it
JPS6048931A (en) * 1983-08-29 1985-03-16 Yoshio Sakagami Tumor cell proliferation inhibiting factor consisting of novel protein
JPH0358360B2 (en) * 1983-08-29 1991-09-05 Yoshio Sakagami
JPS6230725A (en) * 1985-04-10 1987-02-09 Denichi Mizuno Novel protein, production thereof and antitumor agent containing same
WO1990010651A1 (en) * 1989-03-10 1990-09-20 Snow Brand Milk Products Co., Ltd. Glycoprotein of human origin, physiologically active factor comprising the same, and pharmaceutical preparation containing the same as active ingredient

Also Published As

Publication number Publication date
KR840003694A (en) 1984-09-15
ZA831109B (en) 1983-11-30

Similar Documents

Publication Publication Date Title
Marquet et al. Interferon treatment of a transplantable rat colon adenocarcinoma: importance of tumor site
US5128126A (en) Use of pharmaceutical compositions containing at least one cytokine for the systemic treatment of preneoplastic lesions
Sachs et al. Treatment of hepatocellular carcinoma with recombinant leucocyte interferon: a pilot study.
WO2021027704A1 (en) Application of polypeptide or derivative thereof
CA1297005C (en) Pharmaceutical agent for the treatment of myelogenous leukemia
EP0235151B1 (en) Proglumide and pharmaceutical compositions containing it for use in the treatment of neoplastic affections
JPS58148826A (en) Glycoprotein and remedy for tumor
JPH02264730A (en) Inhalant for treating atll
Berger et al. Studies on the tumor-inhibiting efficacy of Iscador in experimental animal tumors
JP2784401B2 (en) How to treat chronic myeloid leukemia
US5399341A (en) Use of cytokin-containing aerosols and the cytokin-containing aerosols
TW202011946A (en) Combination therapy with a bet inhibitor and a proteasome inhibitor
EP0338679A2 (en) Tumour necrosis factor in the treatment of bladder cancer
DE4127469A1 (en) Compsn. contg. chemotherapeutic agent and lithium salt - for treatment of bacterial or viral infection e.g. HSV and HIV, malaria, leishmaniasis, trypanosoma infection and Candida albicans
JP6987271B2 (en) New quinocalcon compounds and their uses for treating cancer or inflammation
US5849282A (en) Method of treating colon, renal, and lung carcinomas with γ-interferon and Ser71 !-interleukin-1β
CN107693790B (en) Combination for the treatment of lung cancer
EP0344643B1 (en) Antiviral pharmaceutical composition
Ek et al. Intravesical adriamycin therapy in carcinoma in situ of the urinary bladder
US7183258B2 (en) Two synthetic peptides for treatment and prevention of cancers
JPH04500210A (en) Treatment of bone marrow suppression related to acquired immunodeficiency
CN114209812B (en) Application of alpha-Momordica charantia extract in preparation of anti-inflammatory drugs
RU2782931C2 (en) Indol-3-carboxic acid derivatives with anti-tumor activity
WO1991016916A1 (en) Antineoplastic agent
Bowman et al. Interaction between dactinomycin and tumor necrosis factor in mesothelioma. Cachexia without oncoiysis